Trump Executive Order Tracker | Akin Public Policy and Lobbying

Regulatory Relief to Promote Domestic Production of Critical Medicines (Trump EO Tracker)

May 5, 2025

Reading Time : 1 min
Trump Executive Order Tracker | Akin Public Policy and Lobbying

This order streamlines the regulation of manufacturing pharmaceutical products and inputs to facilitate the restoration of a robust domestic pharmaceutical manufacturing base.

Within 180 days, the order directs the Secretary of Health and Human Services, through the FDA Commissioner, to review existing regulations and guidance that pertain to the development of domestic pharmaceutical manufacturing and take steps to eliminate any duplicative or unnecessary requirements in such regulations and guidance; maximize the timeliness and predictability of agency review; and streamline and accelerate the development of domestic pharmaceutical manufacturing.

Within 90 days of the order, the FDA Commissioner is directed to develop and advance improvements to the risk-based inspection regime that ensures routine reviews of overseas manufacturing facilities involved in the supply of United States medicines, funded by increased fees on foreign manufacturing facilities and the FDA Commissioner must publicly disclose the annual number of inspections that the FDA conducts on such foreign facilities.

Within 180 days, the order instructs the Administrator of the Environmental Protection Agency (EPA) to take action to update regulations and guidance that apply to the inspection and approval of new and expanded manufacturing capacity of pharmaceutical products, active pharmaceutical ingredients, key starting materials, and associated raw materials in the United States to eliminate any duplicative or unnecessary requirements and maximize the timeliness and predictability of agency review.

Within 180 days of the order, the Secretary of the Army, acting through the Assistant Secretary of the Army for Civil Works, shall review the nationwide permits issued under section 404 of the Clean Water Act of 1972 (33 U.S.C. 1344) and section 10 of the Rivers and Harbors Appropriation Act of 1899 (33 U.S.C. 403) to determine whether an activity-specific nationwide permit is needed to facilitate the efficient permitting of pharmaceutical manufacturing facilities.

Additional Documentation

Share This Insight

Related Content

Trump Executive Order Tracker

The significant number of executive orders published by the Trump Administration cut across dozens of industries and areas of law. This searchable tool breaks down the orders and their impacts on specific industries and with in-depth analysis of specific orders.

Previous Entries

Trump Executive Order Tracker

June 12, 2025

Directs DOI and USDA to consolidate wildland fire programs, expand local partnerships, develop a technology roadmap, and revise rules to enable more effective wildfire prevention and response. It also instructs multiple agencies to promote prescribed burns, manage biomass, improve power system practices, modernize response metrics, and release satellite data to support wildfire mitigation.

...

Read More

Trump Executive Order Tracker

June 12, 2025

Revokes the September 27, 2023 Presidential Memorandum on restoring fish populations in the Columbia River Basin and directs relevant agencies to withdraw from the associated litigation MOU, halt the current SEIS process, and report on all related actions and funding commitments within 30 days. It also tasks agencies with developing a revised environmental review schedule aligned with the administration’s new policy priorities.

...

Read More

Trump Executive Order Tracker

June 6, 2025

This memorandum directs the Secretary of Health and Human Services to take appropriate action to eliminate waste, fraud, and abuse in Medicaid, including by ensuring Medicaid payments rates are not higher than Medicare.

...

Read More

Trump Executive Order Tracker

June 4, 2025

Orders the suspension of entry for any alien into the United States as a nonimmigrant to pursue a course of study at Harvard University or to participate in an exchange visitor program hosted by Harvard University. The suspension and limitation shall expire, absent extension, 6 months after today’s date.

...

Read More

Trump Executive Order Tracker

June 4, 2025

Orders the full suspension of entry for nationals of countries of identified concern.

...

Read More

Trump Executive Order Tracker

June 4, 2025

Orders the Counsel to the President, in consultation with the Attorney General and the head of any other relevant executive department or agency to investigate whether certain individuals conspired to deceive the public about President Biden’s mental state and unconstitutionally exercise the authorities and responsibilities of the President. The investigation will also include the circumstances surrounding President Biden’s execution of numerous executive actions during his final years in office.

...

Read More

Trump Executive Order Tracker

May 23, 2025

Directs the Departments of Defense and Energy to deploy advanced nuclear reactors for critical military and AI infrastructure, starting with operation at a domestic military base by September 30, 2028, and site deployment at DOE facilities within 30 months. Mandates interagency action to secure fuel supplies, streamline NEPA compliance, and pursue at least 20 new nuclear export agreements by the end of the 120th Congress to position U.S. nuclear technology as a global strategic asset.

...

Read More

Trump Executive Order Tracker

May 23, 2025

Orders the Director of the Office of Science and Technology Policy (OSTP Director) to issue guidance for agencies on implementation of “Gold Standard Science” in the conduct and management of their respective scientific activities

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.